A Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with B cell Lymphoid Malignancies
[Protocol 06-066] |
Barker, Juliet, MBBS |
A Phase I Study of Clofarabine Plus Topotecan, Vinorelbine, Thiotepa, and Dexamethasone in Pediatric Patients with Relapsed or Refractory Acute Leukemia
[Protocol 07-012] |
Steinherz, Peter, MD |
A Phase I Study of Consolidation Therapy with Autologous T Cells Genetically Targeted to CD19 in Patients with Chronic Lymphocytic Leukemia After Initial Chemotherapy
[Protocol 11-048] |
Park, Jae, MD |
A Phase I Study of Genetically Modified T Cells to Treat Recurrent or Refractory Chronic Lymphocytic Leukemia
[Protocol 06-138] |
Brentjens, Renier, MD, PhD |
A Phase I Study of Induction Therapy with Cytarabine, High-Dose Mitoxantrone, and Dasatinib for Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia
[Protocol 09-046] |
Lamanna, Nicole, MD |
A Phase I Trial of B-Cell Acute Lymphoblastic Leukemia Treated with Autologous T Cells Gene-Targeted to the B-Cell Antigen CD19
[Protocol 09-114] |
Brentjens, Renier, MD, PhD |
A Phase I Trial of NECTAR: Nelarabine, Etoposide, and Cyclophosphamide in Children with T-Cell Acute Lymphoblastic Leukemia
[Protocol 11-119] |
Trippett, Tanya, MD |
A Phase I-II Study of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Previously Treated Patients with Chronic Lymphocytic Leukemia and Other Low Grade B-Cell Cancers
[Protocol 05-077] |
Lamanna, Nicole, MD |
A Phase I/II Study of Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Patients with Relapsed/Refractory Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
[Protocol 05-103] |
Gerecitano, John, MD, PhD |
A Phase II Pilot Trial of Hematopoietic Stem Cell Transplantation with Total Body Irradiation, Cyclophosphamide & Fludarabine to Treat Patients with Fanconi Anemia Lacking a Genotypically Identical Donor
[Protocol 01-062] |
Boulad, Farid, MD |
A Phase II Study of CAL-101 plus Rituximab in Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
[Protocol 10-224] |
Lamanna, Nicole, MD |
A Phase II Study of Dasatinib in Children and Adolescents Newly Diagnosed with Chronic Phase CML or with Philadelphia Chromosome-Positive Leukemias Resistant to or Intolerant of Imatinib
[Protocol 11-030] |
Shukla, Neerav, MD |
A Phase II Study of Lenalidomide in Patients with Chronic Lymphocytic Leukemia Age 65 and Older
[Protocol 09-045] |
Lamanna, Nicole, MD |
A Phase II Study of Peri-transplant Palifermin followed by an Allogeneic T-Cell-Depleted Stem Cell Transplant in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved from MDS
[Protocol 08-008] |
Castro-Malaspina, Hugo, MD |
A Phase II Study of Tretinoin plus Arsenic Trioxide in Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Therapy
[Protocol 11-040] |
Jurcic, Joseph, MD |
A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia
[Protocol 08-031] |
Boulad, Farid, MD |
A Phase II Trial of Transplants from HLA-Compatible Donors with T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System for the Treatment of Patients with Hematologic Malignancies and Disorders
[Protocol 10-050] |
O'Reilly, Richard, MD |
A Phase III Study of Cytarabine with or without Vosaroxin in Patients with First Relapsed or Refractory Acute Myeloid Leukemia
[Protocol 11-094] |
Rosenblat, Todd, MD |
A Phase III Study of Elacytarabine versus Investigator's Choice in Patients with Late-Stage Acute Myeloid Leukemia
[Protocol 10-113] |
Rosenblat, Todd, MD |
A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Acute Leukemia or Myelodysplasia
[Protocol 08-087] |
Barker, Juliet, MBBS |
A Study of Posaconazole Versus Micafungin to Protect Against Invasive Fungal Infections in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome
[Protocol 10-038] |
Papanicolaou, Genovefa, MD |
Phase I Study of Actinium-225-Labeled HuM195 Antibody in Patients with Advanced Myeloid Malignancies
[Protocol 02-017] |
Jurcic, Joseph, MD |
Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia
[Protocol 11-024] |
Perales, Miguel-Angel, MD |
Phase II Trial of a WT-1 Vaccine in Patients with Acute Myeloid Leukemia
[Protocol 10-143] |
Maslak, Peter, MD |
Treatment of Patients with Newly Diagnosed Standard Risk B-precursor Acute Lymphoblastic Leukemia
[Protocol 11-002] |
Shukla, Neerav, MD |
